<DOC>
	<DOC>NCT02198287</DOC>
	<brief_summary>Safety, tolerability and pharmacokinetic study of BIIX 1 XX in healthy male volunteers.</brief_summary>
	<brief_title>Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy males, based on a complete medical examination Age range from 21 to 50 years Participant must be within +/ 20 % of their normal weight (BrocaIndex) Participant must provide written informed consent Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) or laboratory tests deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of a drug with a long halflife (â‰¥ 24 hours) within at least one month or less than then halflives of the respective drug before enrolment in the study Use of any drugs which might influence the results of the trial within seven days prior to administration or during the trial Participation in another trial with an investigational drug within two months prior to start of the study Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) Inability to refrain from smoking on study days Alcohol abuse Drug abuse Blood donation (&gt; 100 ml) within four weeks prior to administration Other disease or abnormality of clinical relevance Excessive physical activities within two weeks prior to administration or during the trial</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>